Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.
Antibody levels against the novel coronavirus rose and then held steady for up to four months in more than 90% of recovered Covid-19 patients in Iceland, according to a published study.
The United States Food and Drug Administration approved Bayer’s Lampit (nifurtimox) for use in pediatric patients for the treatment of Chagas disease caused by Trypanosoma cruzi.
Researchers at Australia’s Monash University developed a test for SARS-CoV-2, the virus that causes Covid-19, that can provide results in 20 minutes.
Medical device maker Danaher Corp.’s COVID-19 blood test for detecting if a person had ever been infected with the new coronavirus received emergency use clearance from the U.S. Food and Drug Administration.
Many studies assessing the accuracy of COVID-19 antibody tests had major shortcomings, a review concluded, offering further evidence the blood tests are of little use for people seeking to know with certainty if they have been infected.
LabCorp launched a new test that could assess the capacity of antibodies in patient plasma to inhibit the novel coronavirus.
Quest Diagnostics saw a higher recovery in the company’s testing volumes in the United States where state and local governments were slowly lifting restrictions after the coronavirus lockdowns.
Siemens Healthineers stands ready to ramp up production of the company’s antibody test to more than 50 million per month from June 2020 as governments across the world are keen to identify those who may have developed immunity to the coronavirus.
As the world battles the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2, biopharma and biotech companies are approaching the fight with various weapons – repurposed drugs, antivirals, vaccines and clinical antibodies. One of the companies deeply involved in clinical antibody development against COVID-19 is San Diego-based Sorrento Therapeutics.